Lethaby Anne, Marjoribanks Jane, Kronenberg Fredi, Roberts Helen, Eden John, Brown Julie
Department of Obstetrics and Gynaecology, University of Auckland, Private Bag 92019, Auckland, New Zealand, 1142.
Cochrane Database Syst Rev. 2013 Dec 10;2013(12):CD001395. doi: 10.1002/14651858.CD001395.pub4.
Vasomotor symptoms, such as hot flushes and night sweats, are very common during the menopausal transition. Hormone therapy has traditionally been used as a highly effective treatment, but concerns about increased risk of some chronic diseases have markedly increased the interest of women in alternative treatments. Some of the most popular of these treatments are foods or supplements enriched with phytoestrogens-plant-derived chemicals that have estrogenic action.
To assess the efficacy, safety and acceptability of food products, extracts and dietary supplements containing high levels of phytoestrogens when compared with no treatment, placebo or hormone therapy for the amelioration of vasomotor menopausal symptoms (such as hot flushes and night sweats) in perimenopausal and postmenopausal women.
Searches targeted the following electronic databases: the Cochrane Menstrual Disorders and Subfertility Group Specialised Register of randomised trials (29 July 2013), the Cochrane Register of Controlled Trials (CENTRAL; 29 July 2013), MEDLINE (inception to 29 July 2013), EMBASE (inception to 29 July 2013), AMED (1985 to 29 July 2013), PsycINFO (inception to 29 July 2013) and CINAHL (inception to 29 July 2013). Attempts were made to access grey literature by sending letters to pharmaceutical companies and performing searches of ongoing trial registers. Reference lists of included trials were also searched.
Studies were included if they were randomised, included perimenopausal or postmenopausal participants with vasomotor symptoms (hot flushes or night sweats), lasted at least 12 weeks and provided interventions such as foods or supplements with high levels of phytoestrogens (not combined with other herbal treatments). Trials that included women who had breast cancer or a history of breast cancer were excluded.
Selection of trials, extraction of data and assessment of quality were undertaken by at least two review authors. Most trials were too dissimilar for their results to be combined in a meta-analysis, so these findings are provided in narrative 'Summary of results' tables. Studies were grouped into broad categories: dietary soy, soy extracts, red clover extracts, genistein extracts and other types of phytoestrogens. Five trials used Promensil, a red clover extract; results of these trials were combined in a meta-analysis, and summary effect measures were calculated.
A total of 43 randomised controlled trials (4,364 participants) were included in this review. Very few trials provided data suitable for inclusion in a meta-analysis. Among the five trials that yielded data assessing the daily frequency of hot flushes suitable for pooling, no significant difference overall was noted in the incidence of hot flushes between participants taking Promensil (a red clover extract) and those given placebo (mean difference (MD) -0.93, 95% confidence interval (CI) -1.95 to 0.10, I(2) = 31%). No evidence indicated a difference in percentage reduction in hot flushes in two trials between Promensil and placebo (MD 20.15, 95% CI -12.08 to 52.38, I(2) = 82%). Four trials that were not combined in meta-analyses suggested that extracts with high (> 30 mg/d) levels of genistein consistently reduced the frequency of hot flushes. Individual results from the remaining trials were compared in broad subgroups such as dietary soy, soy extracts and other types of phytoestrogens that could not be combined. Some of these trials found that phytoestrogen treatments alleviated the frequency and severity of hot flushes and night sweats when compared with placebo, but many trials were small and were determined to be at high risk of bias. A strong placebo effect was noted in most trials, with a reduction in frequency ranging from 1% to 59% with placebo. No indication suggested that discrepant results were due to the amount of isoflavone in the active treatment arm, the severity of vasomotor symptoms or trial quality factors. Also, no evidence indicated that these treatments caused oestrogenic stimulation of the endometrium or the vagina or other adverse effects when used for up to two years.
AUTHORS' CONCLUSIONS: No conclusive evidence shows that phytoestrogen supplements effectively reduce the frequency or severity of hot flushes and night sweats in perimenopausal or postmenopausal women, although benefits derived from concentrates of genistein should be further investigated.
血管舒缩症状,如潮热和盗汗,在绝经过渡期间非常常见。传统上,激素疗法一直被用作一种高效的治疗方法,但对某些慢性疾病风险增加的担忧显著提高了女性对替代疗法的兴趣。这些疗法中一些最受欢迎的是富含植物雌激素的食物或补充剂,植物雌激素是具有雌激素作用的植物衍生化学物质。
评估与不治疗、安慰剂或激素疗法相比,含有高剂量植物雌激素的食品、提取物和膳食补充剂在改善围绝经期和绝经后女性血管舒缩性绝经症状(如潮热和盗汗)方面的疗效、安全性和可接受性。
检索针对以下电子数据库:Cochrane月经失调与生育力低下小组随机试验专门注册库(2013年7月29日)、Cochrane对照试验注册库(CENTRAL;2013年7月29日)、MEDLINE(创刊至2013年7月29日)、EMBASE(创刊至2013年7月29日)、AMED(1985年至2013年7月29日)、PsycINFO(创刊至2013年7月29日)和CINAHL(创刊至2013年7月29日)。通过向制药公司发送信函并检索正在进行的试验注册库来尝试获取灰色文献。还检索了纳入试验的参考文献列表。
纳入的研究需为随机对照试验,纳入有血管舒缩症状(潮热或盗汗)的围绝经期或绝经后参与者,持续至少12周,并提供高剂量植物雌激素的干预措施(不与其他草药治疗联合使用)。排除纳入患有乳腺癌或有乳腺癌病史女性的试验。
至少两名综述作者进行试验选择、数据提取和质量评估。大多数试验差异太大,其结果无法合并进行荟萃分析,因此这些结果在叙述性的“结果总结”表中呈现。研究分为大致几类:膳食大豆、大豆提取物、红车轴草提取物、染料木黄酮提取物和其他类型的植物雌激素。五项试验使用了红车轴草提取物Promensil;这些试验的结果合并进行荟萃分析,并计算汇总效应量。
本综述共纳入43项随机对照试验(4364名参与者)。很少有试验提供适合纳入荟萃分析的数据。在五项产生了可合并的评估潮热每日发作频率数据的试验中,服用Promensil(红车轴草提取物)的参与者与服用安慰剂的参与者相比,潮热发生率总体上无显著差异(平均差(MD)-0.93,95%置信区间(CI)-1.95至0.10,I² = 31%)。两项试验中,Promensil与安慰剂相比,潮热减少百分比无差异的证据(MD 2-0.15,95% CI -12.08至52.38,I² = 82%)。四项未合并进行荟萃分析的试验表明,高剂量(>30mg/d)染料木黄酮提取物能持续降低潮热频率。其余试验的个体结果在无法合并的大致亚组中进行比较,如膳食大豆、大豆提取物和其他类型的植物雌激素。其中一些试验发现,与安慰剂相比,植物雌激素治疗可减轻潮热和盗汗的频率及严重程度,但许多试验规模较小,且被判定存在高偏倚风险。大多数试验中观察到强烈的安慰剂效应,安慰剂使频率降低1%至59%。没有迹象表明结果差异是由于活性治疗组中异黄酮的含量、血管舒缩症状的严重程度或试验质量因素所致。此外,没有证据表明这些治疗在使用长达两年时会引起子宫内膜或阴道的雌激素刺激或其他不良反应。
没有确凿证据表明植物雌激素补充剂能有效降低围绝经期或绝经后女性潮热和盗汗的频率或严重程度,不过染料木黄酮浓缩物的益处值得进一步研究。